Post-Market Inspection by SEREMI de Salud in Chile
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Post-market inspections in Chile are carried out by SEREMI de Salud within the territory where the infringement occurs (Article 111 letter e) of the Sanitary Code). GRZAN groups the most frequent inspection focus areas into six dimensions: consistency between the registration certificate and the physical product, labelling and instructions for use, batch traceability, warehousing and cold-chain records, tecnovigilancia records, and the distribution and authorisation chain.
The recommended action is one six-dimension self-assessment every year — turning an inspection into a predictable internal process instead of an emergency response. The value of the annual cycle is not only finding defects before the authority does; it is that every answer an inspector could ask for already exists in a retrievable form. A company that can produce the certificate, the label version, the batch record, the temperature log, the vigilance file and the authorisation chain within hours presents a fundamentally different profile from one that assembles documents while the inspector waits, and that difference shapes how the inspection proceeds and how findings are framed.
The six dimensions are not equally exposed. The certificate and its consistency with reality sit at the top of the file; labelling is the visible surface; traceability and cold-chain records determine how far any problem can be ring-fenced; tecnovigilancia records show whether the reporting duties were treated seriously; and the distribution and authorisation chain explains who is accountable for each lot sold. An inspector typically works through them in roughly that order, and a weakness in an early dimension raises the intensity of scrutiny applied to the rest. Preparing the file in the inspection’s own order is therefore more efficient than preparing it in the company’s internal departmental order.
2. Legal basis
- Sanitary Code | DFL N° 725, de 1967 | Article 111 letter e) | SEREMI is responsible for opening cases and imposing sanctions within its territory; Article 111 letter f) | seizure of products sold or distributed without a certificate.
- Regulation on the control of pharmaceutical products and medical devices | Decreto Supremo N° 825, de 1998 | August 21, 1999 | Article 26: labelling must state that conformity verification has been passed and the ISP number; Article 28: post-market reporting obligations; Article 30: seizure.
- Same source | Article 21 letter a) numeral 1 | identification information includes batch number and code; numeral 3 | storage conditions.
- General Technical Norm on patient safety and the safe use of medical devices | Norma General Técnica N° 204 | published January 16, 2019 | tecnovigilancia duties.
- ISP procedure | prestación 9100003 (v3, September 25, 2025) | registration certificate valid for 3 years, with automatic continuous renewal.
3. Expert insights
Insight one: the first scene of an inspection is the label, because it is the only compliance element verifiable without opening a box.
The marking required by Article 26 of DS 825/1998 — conformity verification passed plus the ISP number — can be read standing in front of a shelf. Labels not updated after a change of channel or licence holder are the problems most easily discovered on site. Inspectors do not need laboratory support or document requests to find this defect; a mismatch between the packaging in the warehouse and the certificate on file is visible immediately, and it tends to trigger deeper questions about what else in the file is out of date.
Insight two: batch traceability capability determines the scope of a seizure.
Under Article 111 letter f) and Article 30 of DS 825/1998, a seizure supported by complete batch traceability records can be confined to specific batches; where traceability is missing, the entire warehouse may be included. This is the most direct economic value of a traceability system: the quality of the batch records decides whether a problem costs one lot or the whole stock. The calculation is simple, and it should be made before the inspector makes it.
Insight three: automatic certificate renewal makes outdated certificate information an invisible risk.
The registration certificate renews automatically every 3 years (Article 36 of this series). If the address, licence holder or manufacturer name has changed but was never declared, the inspection will surface a mismatch between the certificate and reality — and under an automatic renewal mechanism such discrepancies stay hidden for years until an inspection exposes them. The absence of a renewal filing deadline removes the natural checkpoint at which the data would otherwise be corrected.
Insight four: multiple regions mean multiple inspection rhythms.
Article 111 letter e) assigns jurisdiction by the place where the infringement occurs. A company with national distribution may face several SEREMI offices at the same time, so response plans should be prepared per region rather than as a single headquarters template. Local contact persons, local language conventions and local document sets differ, and a plan that assumes one counterpart will misfire in every region except one. The practical remedy is a per-region annex to the national plan: who signs the responses locally, which warehouse documents exist in which format, and where the batches were distributed, so that a visit to any region starts from a complete local file rather than a courier request to headquarters.
4. Practical recommendations
- Run one six-dimension self-assessment every year: certificate consistency, labelling and instructions, batch traceability, warehousing and cold chain, tecnovigilancia records, distribution and authorisation chain — each dimension scored and documented.
- Update labels immediately after any change of channel or licence holder, and retain version records so the label history can be reconstructed on request.
- Keep batch traceability retrievable on demand, ensuring any problem can be confined to specific batches rather than spreading to the full stock.
- Review certificate information every 3 years (address, licence holder, manufacturer name, process, label version), even though renewal is automatic and no filing prompts it.
- Prepare SEREMI response plans per region: local contact persons, standard response templates, and a ready document package.
5. Verification checklist
- □ The annual six-dimension self-assessment has been executed and archived
- □ Labels were updated after the change of channel or licence holder
- □ Batch traceability records are retrievable on demand
- □ A mechanism to review certificate information every 3 years exists
- □ SEREMI response plans are prepared per region
Regulatory information verified as of October 29, 2026.
GRZAN supports manufacturers, importers and authorised representatives with post-market compliance in Chile, including tecnovigilancia reporting, FSCA and recall execution, record-keeping systems and SEREMI inspection response. For a product-specific feasibility assessment or post-market compliance support for the Chilean market, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us